NCT01645930 · REGISTRY CONDITION SEARCH

Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2018-11-08

The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with relapsed and/or refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Cmax: Maximum Observed Plasma Concentration for Ixazomib

→

outcome · POSTED

Cmax: Maximum Observed Plasma Concentration for Ixazomib

→

outcome · POSTED

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib

→

outcome · POSTED

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib

→

outcome · POSTED

AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib

→

outcome · POSTED

AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib

→

outcome · POSTED

Number of Participants With Dose Limiting Toxicities (DLTs)

→

outcome · POSTED

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

→

outcome · POSTED

Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Adverse Events of ≥Grade 3 Intensity

→

outcome · POSTED

Number of Participants With Clinically Significant Vital Signs Reported as Adverse Events

→

outcome · POSTED

Percentage of Participants With Confirmed Best Response Category

→

outcome · POSTED

Duration of Response (DOR)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Male or female East Asian participants 18 years or older * Diagnosed Multiple Myeloma according to standard criteria * Measurable disease as specified in study protocol * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Participants with relapsed and/or refractory Multiple Myeloma who have received 1 to 3 prior therapies * Meet the clinical laboratories criteria as specified in the protocol * Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to abstain from heterosexual intercourse; must also adhere to the guidelines of the lenalidomide pregnancy prevention program * Male participants who agree to practice effective barrier contraception or agree to abstain from heterosexual intercourse and must adhere to the guidelines of the lenalidomide pregnancy prevention program * Must be able to take concurrent aspirin 325 mg daily * Voluntary written consent Exclusion Criteria: * Female participants who are lactating or pregnant * Major surgery or radiotherapy within 14 days before enrollment * Infection requiring systematic antibiotics within 14 days before study enrollment * Central nervous system involvement * Failure to have fully recovered from the effects of prior chemotherapy regardless of the interval since last treatment * Systemic treatment with strong inhibitors of cytochrome P450 1A2 (CYP1A2), strong inhibitors of CYP3A, or strong CYP3A inducers, or use of Ginko biloba or St. John's wort within 14 days before study enrollment * Diagnosis of Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome * Evidence of current uncontrolled cardiovascular conditions * Serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol * Known allergy to any of the study medications * Known gastrointestinal condition or procedure that could interfere with swallowing or the oral absorption of tolerance of ixazomib * Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ * Ongoing or active systemic infection, active hepatitis B virus infect, active hepatitis C infection, or known human immunodeficiency virus (HIV) positive
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)
intervention Names
Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone
label
Ixazomib+Lenalidomide+Dexamethasone
type
EXPERIMENTAL

interventions

arm Group Labels
Ixazomib+Lenalidomide+Dexamethasone
description
Ixazomib capsules
name
Ixazomib
type
DRUG
arm Group Labels
Ixazomib+Lenalidomide+Dexamethasone
description
Lenalidomide capsules
name
Lenalidomide
type
DRUG
arm Group Labels
Ixazomib+Lenalidomide+Dexamethasone
description
Dexamethasone tablets
name
Dexamethasone
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 43
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

measure
Cmax: Maximum Observed Plasma Concentration for Ixazomib
time Frame
Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
measure
Cmax: Maximum Observed Plasma Concentration for Ixazomib
time Frame
Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
measure
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib
time Frame
Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
measure
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib
time Frame
Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
measure
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib
time Frame
Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
measure
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Ixazomib
time Frame
Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
description
DLT was defined as any of the following AEs that were considered by investigator to be possibly related to therapy: 1. Grade 4 neutropenia lasting at least 7 consecutive days; 2. Grade 3 neutropenia with fever and/or infection; 3. Grade 4 thrombocytopenia at least 7 consecutive days; 4. Grade 3 thrombocytopenia with clinically significant bleeding; 5. Platelet count \<10,000/mm\^3; 6. Grade 2 peripheral neuropathy with pain or ≥Grade 3 peripheral neuropathy; 7. Grade 3 or greater nausea and / or emesis despite the use of optimal anti-emetic prophylaxis; 8. Grade 3 or greater diarrhea that occurred despite maximal supportive therapy; 9. Any other Grade 3 or greater nonhematologic toxicity with the following exceptions: Grade 3 arthralgia/myalgia, \<1 week Grade 3 fatigue; 10. A delay of \>2 weeks in the subsequent cycle of treatment; 11. Other combination study drug-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required discontinuation of study drug.
measure
Number of Participants With Dose Limiting Toxicities (DLTs)
time Frame
Cycle 1 (up to Day 28)
description
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or was a medically important event.
measure
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
time Frame
From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
description
Clinically significant laboratory abnormalities were defined as any test results which were observed beyond the clinically acceptable limits as per the discretion of investigator. Clinical laboratory tests included chemistry, hematology and urinalysis tests.
measure
Number of Participants With Clinically Significant Laboratory Abnormalities Reported as Adverse Events of ≥Grade 3 Intensity
time Frame
From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
description
The number of participants who meet markedly abnormal criteria for vital signs, included diastolic and systolic blood pressure, heart rate, oral temperature, respiratory rate, and body weight.
measure
Number of Participants With Clinically Significant Vital Signs Reported as Adverse Events
time Frame
From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)

secondary Outcomes

description
Percentage of participants who achieve or maintain any best response category during the treatment period were reported. Best response includes complete response (CR), very good partial response (VGPR), and partial response (PR). Response was assessed according to IMWG criteria. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour.
measure
Percentage of Participants With Confirmed Best Response Category
time Frame
From Cycle 1, Day 1 to Cycle 3, Day 1 until disease progression (approximately 20 months)
description
DOR was defined as the length of time between the date of first documented response (PR, VGPR, or CR) and the date of first documented progressive disease (PD). According to IMWG criteria: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to \<200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hour.
measure
Duration of Response (DOR)
time Frame
From date of documentation of a confirmed response to date of progressive disease, (approximately 20 months)

Full study description

brief Summary: The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with relapsed and/or refractory multiple myeloma.
detailed Description: The drug being tested in this study was ixazomib. Ixazomib was tested to treat adult Asian people who had relapsed and/or refractory multiple myeloma. The study enrolled 43 patients. Participants were enrolled to receive: * Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg. All participants were asked to take ixazomib capsules orally on Days 1, 8, and 15; lenalidomide capsules, orally, on Days 1 through 21; and dexamethasone tablets, orally, on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles). This multi-center trial was conducted in Singapore, Hong Kong and South Korea. The overall time to participate in this study was up to 577 days. Participants made multiple visits to the clinic, and were contacted 30 days after last dose of study drug for a follow-up assessment.

Source references

references

citation
Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1.
pmid
26337806
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-359d929640fa8d494029
requested nct id
NCT01645930
primary nct id
NCT01645930
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
ae2d57facb493d35d3ab22744183562202f35f6ed9b0a2623be71b869c27f004
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-359d929640fa8d494029
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01645930
occurrences
context exact
NCT01645930
end
11
exact text
NCT01645930
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/990/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
043519544c8b37a729b26215764964ab317bcc04bf5f0ef8be3b7ebd7d590705
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice